Latest News
BeOne Medicines AG
- BeOne Medicines Presents New Phase 3 Data in HER2-Positive Gastroesophageal Cancer at ESMO 2026
- BeOne Medicines Ltd. Class A Estimates – SSE:688235
- Pilar de la Rocha Mur Highlights BeOne Medicines’ Commitment to Oncology and Solid Tumors’ Growing Importance at ESMO 2026
- BeOne reports extended survival data from cancer drug trial By Investing.com
- BeOne Medicines to Announce Third Quarter 2026 Financial Results on November 5
- BeOne Medicines (NDQ:ONC): Can this US$45bn China-founded biotech become a global oncology powerhouse?
- BeOne Medicines Highlights Rapidly Accelerating Solid Tumor Franchise at ESMO 2026
- Form 4 BeOne Medicines Ltd.: Xiaodong Wang (Director, Chair, Scientific Advisory Brd) For: 13 October
- Why is BeOne Medicines stock up 5.1% today?
- BeOne Medicines’ Multi-Timeframe Setup Points to a Broader Bullish Re-Rating
- Amanda Pullinger: Cancer Care Leaders Gather at BeOne Medicines to Discuss Artificial Intelligence
- BeOne Medicines Successfully Completes Negotiations with the pan-Canadian Pharmaceutical Alliance (pCPA) for TEVIMBRA® in first-line Recurrent or Metastatic Nasopharyngeal Carcinoma
Headlines from the last 30 days, linking to the original publishers. See all market news →